Hopes For Glaxo’s MAGE-A3 Vaccine Grow Dim As Trial Misses Endpoint

Glaxo’s vaccine fails co-primary endpoint in Phase III DERMA study of melanoma – trial is allowed to continue but hopes for success are not high. Top-line release raises specter that drug could become yet another failed cancer vaccine.